Bisantrene, biological and clinical effects

Charles A. Coltman, C. Kent Osborne

Resultado de la investigación: Articlerevisión exhaustiva

3 Citas (Scopus)

Resumen

The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in certain tumors. These include metastatic breast cancer, non-Hodgkin's lymphoma, other types of lymphoma, leukemia, and, probably, ovarian cancer. There does not appear to be significant activity in malignant melanoma or in metastatic renal cancer. The conclusion of this symposium was that bisantrene is an active and reasonably well tolerated drug and that further trials are indicated.

Idioma originalEnglish (US)
Páginas (desde-hasta)285-288
Número de páginas4
PublicaciónCancer Treatment Reviews
Volumen11
N.º4
DOI
EstadoPublished - dic. 1984
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Huella

Profundice en los temas de investigación de 'Bisantrene, biological and clinical effects'. En conjunto forman una huella única.

Citar esto